This is not the most recent version of the article. View current version (8 DEC 2010)

Intervention Protocol

Hyperfractionated and/or accelerated radiotherapy versus conventional radiotherapy for head and neck cancer

  1. Jean Pierre Pignon1,*,
  2. Richard Sylvester2,
  3. Jean Bourhis3

Editorial Group: Cochrane Ear, Nose and Throat Disorders Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD002026

How to Cite

Pignon JP, Sylvester R, Bourhis J. Hyperfractionated and/or accelerated radiotherapy versus conventional radiotherapy for head and neck cancer (Protocol). Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002026. DOI: 10.1002/14651858.CD002026.

Author Information

  1. 1

    Institut Gustave-Roussy, Service de Biostatistique et d'Epidemiologie, Villejuif Cedex, France

  2. 2

    European Organisation for Research and Treatment of Cancer Data Center, 1200 Brussels, Belgium

  3. 3

    Institut Gustave-Roussy, Département de Radiothérapie, 94805 Villejuif Cedex, France

*Jean Pierre Pignon, Service de Biostatistique et d'Epidemiologie, Institut Gustave-Roussy, 39, rue Camille Desmoulins, Villejuif Cedex, 94805, France. jppignon@igr.fr.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

This is not the most recent version of the article.View current version (08 Dec 2010)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Assessment of the role of modified fractionated radiotherapy in head and neck squamous carcinoma by studying the following questions:

Main objective

To assess the effect of modified fractionated radiotherapy on the survival of patients with HNSCC by comparing conventional radiotherapy with hyperfractionated and / or accelerated radiotherapy.

Secondary objectives

To investigate the interaction between the treatment effect and the type of radiotherapy (indirect comparison) and to investigate the interaction between the treatment effect and the prognostic factors (subgroup analysis).